Status:
UNKNOWN
Genotypic Resistance-guided Versus Empirical Therapy for H. Pylori Eradication.
Lead Sponsor:
Konstantopoulio-Patission General Hospital of Nea Ionia
Conditions:
Helicobacter Pylori Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study aims to investigate the efficacy of a 7-day genotypic resistance-guided triple therapy, compared with empirical concomitant therapy, for first-line eradication of H. pylori.
Detailed Description
Empiric eradication of H. pylori becomes steadily more challenging because of increasing antibiotic resistance. In high-resistance countries where bismuth and/or tetracycline are unavailable (eg; Gree...
Eligibility Criteria
Inclusion
- Consecutive outpatients aged ≥18 years with documented H. pylori infection. Mental and legal ability to provide written informed consent.
Exclusion
- previous history of H. pylori eradication therapy
- history of allergies to the medications used
- previous esophageal or gastric surgery
- serious systemic disease
- pregnancy or lactation.
Key Trial Info
Start Date :
September 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 28 2020
Estimated Enrollment :
304 Patients enrolled
Trial Details
Trial ID
NCT04090021
Start Date
September 1 2019
End Date
February 28 2020
Last Update
September 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Konstantopoulio-Patision General Hospital
Athens, Nea Ionia, Greece, 14233